Search Results Search Sort by RelevanceMost Recent Podcast Jul 2024 Author Interview: “How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD?” Dr Katherin M. Duthie joins Ethics Talk to discuss her article, coauthored with Dr Kathryn A. Dong: “How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD?” Medicine and Society Jul 2024 What Would Equitable Harm Reduction Look Like? Oluwole Jegede, MD, MPH, Julio C. Nunes, MD, Terence Tumenta, MD, MPH, Carmen Black, MD, and Joao P. DeAquino, MD Structural determinants of health frameworks must be person centered and express antiracism to be effective. AMA J Ethics. 2024;26(7):E572-579. doi: 10.1001/amajethics.2024.572. Medicine and Society Jul 2024 How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder? Elizabeth Salisbury-Afshar, MD, MPH, Catherine J. Livingston, MD, MPH, and Ricky N. Bluthenthal, PhD Equity requires full access to evidence-based OUD care, housing stability, and education and employment opportunities. AMA J Ethics. 2024;26(7):E562-571. doi: 10.1001/amajethics.2024.562. In the Literature Jul 2024 How Should Harm Reduction Strategies Differ for Adolescents and Adults? Brady J. Heward, MD, Amy M. Yule, MD, and Peter R. Jackson, MD Recent increases in adolescent mortality from overdose have outpaced increases in mortality in members of the general population. AMA J Ethics. 2024;26(7):E534-545. doi: 10.1001/amajethics.2024.534. Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. AMA J Ethics. 2024;26(7):E512-519. doi: 10.1001/amajethics.2024.512. History of Medicine Jul 2024 Drawing on Black and Queer Communities’ Harm Reduction Histories to Improve Overdose Prevention Strategies and Policies Sterling Johnson, JD, MA and Kimberly L. Sue, MD, PhD Black and queer community-based harm reduction practices can help guide development and implementation of anti-overdose interventions. AMA J Ethics. 2024;26(7):E580-586. doi: 10.1001/amajethics.2024.580. Pagination First page « First Previous page ‹ Previous … Page 27 Page 28 Page 29 Page 30 Page 31 Page 32 Page 33 Page 34 Current page 35
Podcast Jul 2024 Author Interview: “How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD?” Dr Katherin M. Duthie joins Ethics Talk to discuss her article, coauthored with Dr Kathryn A. Dong: “How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD?”
Medicine and Society Jul 2024 What Would Equitable Harm Reduction Look Like? Oluwole Jegede, MD, MPH, Julio C. Nunes, MD, Terence Tumenta, MD, MPH, Carmen Black, MD, and Joao P. DeAquino, MD Structural determinants of health frameworks must be person centered and express antiracism to be effective. AMA J Ethics. 2024;26(7):E572-579. doi: 10.1001/amajethics.2024.572.
Medicine and Society Jul 2024 How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder? Elizabeth Salisbury-Afshar, MD, MPH, Catherine J. Livingston, MD, MPH, and Ricky N. Bluthenthal, PhD Equity requires full access to evidence-based OUD care, housing stability, and education and employment opportunities. AMA J Ethics. 2024;26(7):E562-571. doi: 10.1001/amajethics.2024.562.
In the Literature Jul 2024 How Should Harm Reduction Strategies Differ for Adolescents and Adults? Brady J. Heward, MD, Amy M. Yule, MD, and Peter R. Jackson, MD Recent increases in adolescent mortality from overdose have outpaced increases in mortality in members of the general population. AMA J Ethics. 2024;26(7):E534-545. doi: 10.1001/amajethics.2024.534.
Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. AMA J Ethics. 2024;26(7):E512-519. doi: 10.1001/amajethics.2024.512.
History of Medicine Jul 2024 Drawing on Black and Queer Communities’ Harm Reduction Histories to Improve Overdose Prevention Strategies and Policies Sterling Johnson, JD, MA and Kimberly L. Sue, MD, PhD Black and queer community-based harm reduction practices can help guide development and implementation of anti-overdose interventions. AMA J Ethics. 2024;26(7):E580-586. doi: 10.1001/amajethics.2024.580.